Synairgen (LON:SNG) Stock Price Down 0.9% – Should You Sell?

Synairgen plc (LON:SNG) shares were down 0.9% during mid-day trading on Wednesday . The stock traded as low as GBX 2.01 ($0.02) and last traded at GBX 2.23 ($0.03). Approximately 81,096 shares traded hands during trading, a decline of 87% from the average daily volume of 620,372 shares. The stock had previously closed at GBX 2.25 ($0.03).

Synairgen Price Performance

The stock has a market capitalization of £4.29 million, a P/E ratio of -71.00 and a beta of -2.23. The company has a 50 day moving average of GBX 3.83 and a 200-day moving average of GBX 4.06. The company has a quick ratio of 6.35, a current ratio of 6.77 and a debt-to-equity ratio of 0.09.

About Synairgen

Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease.

Synairgen is conducting a double blind, placebo-controlled clinical trial in COVID-19 patients (SG016).